Hubrecht Institute licenses Flow Eighteen38 reagent antibodies for cancer research
Antibodies generated by Flow Eighteen38 to be used as research tools by Hubrecht Institute.
Agreement to leverage FairJourney Biologics llama naïve libraries.
Porto, Portugal and Utrecht, Netherlands, – 10 May 2021: Flow Eighteen38 and FairJourney Biologics S.A. (FJB), leaders in the discovery and optimization of antibodies, have today announced an agreement with the Hubrecht Institute to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies to be used as research tools for the group of Hans Clevers.
The Clevers group dedicates its activity to the study of the molecular mechanisms of tissue development and cancer of various organs using organoids made from adult Lgr5 stem cells. Under the agreement, Flow Eighteen38/FJB will provide the Clevers group at the Hubrecht Institute with research tools, arising from an accelerated antibody research campaign, that will support the group’s future scientific developments.
The reagent antibodies generated by Flow Eighteen38/FJB for the Hubrecht Institute comply with the recent EU recommendations on Non-Animal-derived antibodies and will be derived from FJB’s proprietary llama naïve libraries through its phage display technology platform. The Clevers group will benefit from the combination of this technology and the increased speed of delivery from this innovative approach, thought and optimized by the experienced scientists at Flow Eighteen38/FJB.
António Parada, CEO of FairJourney Biologics commented: “Our experience in antibody development has been continuously reinforced throughout the years and our reagent antibodies platform is proving to be essential for the swift generation of unparalleled research tools. We look forward to supply the Clevers group at the Hubrecht Institute with robust reagents that can contribute to further scientific developments in their cancer organoids studies.”
Hans Clevers, Principal Investigator at the Hubrecht Institute commented: “The development of novel and more suitable antibodies presents itself as an advantageous approach for the next generation of research tools. FairJourney Biologics’ experience in antibody discovery, combined with the speed of Flow Eighteen38’s reagent antibodies program, makes them ideal partners as we focus on finding novel research tools that can leverage our stem cell-based organoids platform.”
Click here to learn more about Flow Eighteen38’s Reagent Antibody Services
About FairJourney Biologics http://fjb.pt/
FairJourney Biologics is a leading biologics CRO, providing integrated services across antibody discovery, engineering and production to global biopharma. Founded in 2012 and headquartered in Porto, FairJourney has grown to over 90 highly technically skilled employees today. The Company operates a flexible, customer-oriented ‘one-stop shop’ approach to biologics development focused on quality, reliability and partnership. FairJourney has successfully completed more than 460 projects for over 70 customers across big pharma and leading biotech companies to date. The Company’s significant expertise in phage display technology, combined with a diverse approach to generating both immune and naïve antibody libraries have contributed to a market leading 99%+ project success rate.
About Hubrecht Institute https://www.hubrecht.eu/
Research at the Hubrecht Institute is pioneering in developmental and stem cell biology. The institute encompasses 23 research groups that perform fundamental, multidisciplinary research on healthy and diseased cells, tissues and organisms. The Hubrecht Institute is a research institute of the Royal Netherlands Academy of Arts and Sciences (KNAW), situated on the Utrecht Science Park. Since 2008, the Hubrecht is affiliated with the UMC Utrecht. This allowed the institute to grow into an internationally renowned research institute and facilitated the link with (pre)clinical research. The Hubrecht Institute has a partnership with the European Molecular Biology Laboratory (EMBL) based on shared institutional goals, scientific synergy and complementarity.